Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Jumping Today

By Keith Speights - Apr 9, 2021 at 12:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bad news for its COVID-19 vaccine rivals could be good news for Moderna.

What happened

Shares of Moderna (MRNA -0.37%) were jumping 5.7% higher at 11:17 a.m. EDT on Friday. One potential reason behind the gain is that investors expect that Moderna will benefit from issues that AstraZeneca (AZN 3.08%) and Johnson & Johnson (JNJ -1.10%) are experiencing with their COVID-19 vaccines.

On Wednesday, the European Medicines Agency (EMA) reported a possible link between AstraZeneca's COVID-19 vaccine and unusual blood clots. United Kingdom authorities issued a recommendation that people under age 30 receive another vaccine if possible.

Meanwhile, the U.S. Centers for Disease Prevention and Control (CDC) expects the allocation of Johnson & Johnson's COVID-19 vaccine to plunge by 85% next week. This drastic reduction stems from manufacturing problems found in a facility operated by Emergent BioSolutions, a contract manufacturer J&J engaged to help produce its vaccine.

Two COVID-19 vaccine vials upright and two vials toppled over

Image source: Getty Images.

So what

It's unlikely that Johnson & Johnson's problems will boost Moderna's fortunes in the immediate future. The U.S. government already has supply deals in place to obtain 300 million doses of Moderna's COVID-19 vaccine plus another 300 million doses of the vaccine developed by Pfizer and BioNTech. That's enough to fully vaccinate all Americans in the age groups for which COVID-19 vaccines are currently authorized even without J&J's vaccine.

Johnson & Johnson has stepped in to help resolve the manufacturing issues with the production of its COVID-19 vaccine. The company still expects to deliver nearly 100 million doses of its vaccine by the end of May. 

AstraZeneca's woes, however, could potentially help Moderna. It's possible that some governments could choose to go with rival COVID-19 vaccines for future supply agreements because of the safety concern identified by the EMA. It should be noted, though, that the reported blood clots are a very rare side effect. The EMA maintains that the benefits of AstraZeneca's vaccine outweigh the risks.

Now what

Moderna's chief medical officer, Tal Zaks, made an announcement on Wednesday that could be more important to the biotech stock than the AstraZeneca or Johnson & Johnson stories. Zaks said that Moderna expects its booster shot targeting coronavirus variants should be available by the end of 2021. The emergence of these variants could mean that Moderna will be able to count on strong recurring revenue from its COVID-19 vaccine after the pandemic ends.

Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$171.18 (-0.37%) $0.63
Johnson & Johnson Stock Quote
Johnson & Johnson
$165.30 (-1.10%) $-1.84
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.64 (3.08%) $1.99
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.11 (3.77%) $1.82
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$30.50 (2.04%) $0.61
BioNTech SE Stock Quote
BioNTech SE
$160.35 (1.11%) $1.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.